Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies Oct 11, 2016
Heat Biologics Substantially Reduces Debt and Reports Proceeds of Approximately $2.8 Million Year-to-Date from the Exercise of Warrants Oct 7, 2016
Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor Sep 14, 2016
Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 15, 2016
Heat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology Jul 7, 2016
Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting Jun 6, 2016
